Table 1 Demographic characteristics of patients who initiated ofatumumab using the Sensoready device
Patient demographic characteristics | Overall study population (N = 105) | DMT-naïve (n = 40) | DMT-experienced (n = 65) |
|---|---|---|---|
Mean (SD) age (years) | 42.5 (12.2) | 40.5 (13.7) | 43.8 (11.2) |
Female | 63.8% | 72.5% | 58.5% |
Race | |||
 Caucasian | 51.4% | 40.0% | 58.5% |
 African American | 26.7% | 22.5% | 29.2% |
 Latino or Hispanic | 13.3% | 17.5% | 10.8% |
 Others1 | 13.4% | 27.5% | 4.5% |
US geographical region | |||
 Northeast | 72.4% | 72.5% | 72.3% |
 South | 20.0% | 20.0% | 20.0% |
 Midwest | 3.8% | 0.0% | 6.2% |
 West | 3.8% | 7.5% | 1.5% |
Insurance type | |||
 Commercial | 66.7% | 72.5% | 63.1% |
 Medicare or Medicaid2 | 21.0% | 17.5% | 23.1% |
 Others3 | 12.4% | 10.0% | 13.8% |
Education | |||
 High school to associate degree | 58.0% | 60.0% | 57.0% |
 Bachelor or advanced degree | 40.1% | 37.5% | 41.5% |
 Others4 | 1.9% | 2.5% | 1.5% |
Marital status | |||
 Married | 61.0% | 50.0% | 67.7% |
 Single or never married | 19.0% | 30.0% | 12.3% |
 Others5 | 20.0% | 20.0% | 20.0% |